IQVIA Holdings Inc.
Financials
Valuation Metrics
IQVIA Holdings Inc.'s Market Cap is $43.12B. At end of 2025 it was $38.32B. Ranked #342 of 3,116 in US market (top 11%), #247 of 1,644 on NYSE (top 15%), #23 of 203 in Health Care Equipment & Services (top 11%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $43.12B | US#342/3,116 Sec#23/203 |
| Revenue | $17.31B | US#368/3,116 Sec#26/203 |
| Net Income | $1.39B | US#435/3,116 Sec#23/203 |
| Total Assets | $30.47B | US#468/3,116 Sec#24/203 |
| Net Assets | $6.66B | US#568/3,116 Sec#34/203 |
| Employees | 93,000 | US#130/3,116 Sec#9/203 |
| Value | ||
| P/E | 30.94x | US#1,638/3,116 Sec#62/203 |
| P/B | 6.47x | US#2,427/3,116 Sec#151/203 |
| PEG | 3.58x | US#1,146/3,116 Sec#59/203 |
| P/S | 2.49x | US#1,540/3,116 Sec#105/203 |
| EV/EBITDA | 15.90x | US#1,675/3,116 Sec#68/203 |
| FCF Yield | 4.82% | US#1,481/3,116 Sec#73/203 |
| Profitability | ||
| ROE | 20.93% | US#536/3,116 Sec#25/203 |
| ROA | 4.57% | US#1,124/3,116 Sec#73/203 |
| Op. Margin | 13.43% | US#1,306/3,116 Sec#49/203 |
| Revenue Growth | 8.85% | US#1,352/3,116 Sec#92/203 |
| Earnings Growth | 8.65% | US#1,100/3,116 Sec#61/203 |
| Financial Health | ||
| Debt Ratio | 355.60% | US#2,209/3,116 Sec#174/203 |
| Total Debt | $16.31B | US#276/3,116 Sec#11/203 |
| FCF | $2.08B | US#344/3,116 Sec#22/203 |
| Cash | $2.25B | US#376/3,116 Sec#20/203 |
| Current Ratio | 0.83x | US#2,468/3,116 Sec#200/203 |
| Net Debt/EBITDA | 3.91x | US#1,820/3,116 Sec#118/203 |
| Performance | ||
| 1Y Return | 19.37% | US#1,000/3,116 Sec#85/203 |
| 1M Return | 0.07% | US#1,614/3,116 Sec#144/203 |
| From 52W High | -9.18% | US#328/3,116 Sec#41/203 |
| 1Y MDD | -35.87% | US#1,703/3,116 Sec#100/203 |
| Trading | ||
| Volume | 1,083,459 shares | US#1,394/3,116 Sec#90/203 |
| Trading Value | $284M | US#359/3,116 Sec#32/203 |
| Per Share | ||
| EPS | $8.35 | US#374/3,116 Sec#23/203 |
| BPS | $39.90 | US#622/3,116 Sec#42/203 |
Company Info
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.